TBI is one of the most common causes of death and long term damage to health worldwide. The approved guidelines for patients with TBI include standards of treatment. However, there is lack of guidelines for monitoring or neuroprotective treatment. Cerebrolysin is a drug with a proven beneficial effect on treatment outcome in patients with TBI. There are also reports of the beneficial effect of Amantadine. Studies on the use of additional neuromonitoring are also published with increasing frequency. We decided to investigate how the result of treatment changed with the administration of Cerebrolysin and Amantadine and with additional neuromonitoring. In an observational study, we collected data on 56 patients. After the statistical analysis, it could be shown, that Cerebrolysin monotherapy increases Glasgow Outcome Scale (GOS) among our patients and it was found to interact significantly with Amantadine and neuromonitoring approach in the group of severe TBI. In conclusion, it is worth considering a multimodal approach to the treatment and monitoring of patients with TBI. However, more randomized studies are needed to confirm the method of monitoring or conducting neuroprotective therapy in patients with TBI.